What This Bill Does · Plain English
GovGreed Synthesis · AI extraction
This bill requires the Secretary of Health and Human Services to publish a report within one year. The report must outline a plan for the FDA to complete a review of already-approved opioid painkiller drugs, specifically requiring the review to consider the public health effects of these opioids as part of the benefit-risk assessment. It also mandates that the report address FDA activities related to increasing the development of non-addictive medical products for pain or addiction treatment.
Action Timeline
2023-12-19
Introduced in Senate
2023-12-19
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Frequently Asked Questions
Did S.3557 pass?
S.3557 did not pass and is no longer active. Final stage: COMMITTEE.
What does S.3557 do?
This bill requires the Secretary of Health and Human Services to publish a report within one year. The report must outline a plan for the FDA to complete a review of already-approved opioid painkiller drugs, specifically requiring the review to consider the public health effects of these opioids as part of the benefit-risk assessment. It also mandates that the report address FDA activities related to increasing the development of non-addictive medical products for pain or addiction treatment.
Full Bill Text
118 S3557 IS: To require the Secretary of Health and Human Services to prepare a report that outlines a plan for completing a review of approved opioid analgesic drugs that considers the public health effects of such opioid drugs. U.S. Senate 2023-12-19 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. II 118th CONGRESS 1st Session S. 3557 IN THE SENATE OF THE UNITED STATES December 19, 2023 Mr. Murphy (for himself and Mr. Braun ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To require the Secretary of Health and Human Services to prepare a report that outlines a plan for completing a review of approved opioid analgesic drugs that considers the public health effects of such opioid drugs. 1. Review of opioid drugs and actions Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the Secretary ) shall publish on the website of the Food and Drug Administration (referred to in this section as the FDA ) a report that outlines a plan for completing a review of opioid analgesic drugs that are approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) that considers the public health effects of such opioid drugs as part of the benefit-risk assessment, and that addresses the activities of the FDA that relate to increasing the development of non-addictive medical products intended to treat pain or addiction. Such report shall include— (1) an opportunity for public input concerning the regulation by the FDA of opioid analgesic drugs, including scientific evidence that relates to conditions of use, safety, or benefit-risk assessment (including consideration of the public health effects) of such opioid drugs; (2) an update on the actions taken by the FDA to review the effectiveness, safety, benefit-risk profile (which may include public health effects), and use of approved opioid analgesic drugs; (3) a timeline for an assessment of the potential need, as appropriate, for labeling changes, revised or additional postmarketing requirements, enforcement actions, or withdrawals for opioid analgesic drugs; (4) an overview of the steps that the FDA has taken to support the development and approval of non-addictive medical products intended to treat pain or addiction, and actions planned to further support the development and approval of such products; and (5) an overview of the consideration by the FDA of clinical trial methodologies for analgesic drugs, including the enriched enrollment randomized withdrawal methodology, and the benefits and drawbacks associated with different trial methodologies for such drugs, incorporating any public input received under paragraph (1).
Loading intelligence layer…